Pyxis Oncology (PYXS) Short Interest Ratio & Short Volume $1.06 -0.03 (-2.75%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.08 +0.01 (+1.42%) As of 04/25/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Pyxis Oncology Short Interest DataPyxis Oncology (PYXS) has a short interest of 7.34 million shares, representing 16.77% of the float (the number of shares available for trading by the public). This marks a 6.07% increase in short interest from the previous month. The short interest ratio (days to cover) is 12.3, indicating that it would take 12.3 days of the average trading volume of 734,241 shares to cover all short positions.Current Short Interest7,340,000 sharesPrevious Short Interest6,920,000 sharesChange Vs. Previous Month+6.07%Dollar Volume Sold Short$7.19 millionShort Interest Ratio12.3 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares61,590,000 sharesFloat Size43,770,000 sharesShort Percent of Float16.77%Today's Trading Volume225,814 sharesAverage Trading Volume734,241 sharesToday's Volume Vs. Average31% Short Selling Pyxis Oncology? Sign up to receive the latest short interest report for Pyxis Oncology and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPYXS Short Interest Over TimePYXS Days to Cover Over TimePYXS Percentage of Float Shorted Over Time Pyxis Oncology Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/20257,340,000 shares $7.19 million +6.1%16.8%12.3 $0.98 3/15/20256,920,000 shares $7.68 million -1.3%15.8%10.5 $1.11 2/28/20257,010,000 shares $8.34 million +1.9%16.6%9.1 $1.19 2/15/20256,880,000 shares $9.08 million -1.7%16.3%5.3 $1.32 1/31/20257,000,000 shares $10.99 million -5.7%17.0%5.5 $1.57 1/15/20257,420,000 shares $10.91 million +1.1%18.0%5.9 $1.47 12/31/20247,340,000 shares $11.45 million +14.7%17.9%5.8 $1.56 12/15/20246,400,000 shares $10.37 million +5.3%15.6%5.2 $1.62 11/30/20246,080,000 shares $12.22 million +4.1%14.8%5.2 $2.01 11/15/20245,840,000 shares $24.47 million -0.3%13.3%6.1 $4.19 Get the Latest News and Ratings for PYXS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter. 10/31/20245,860,000 shares $20.86 million +19.4%13.3%11.6 $3.56 10/15/20244,910,000 shares $15.91 million +16.4%10.5%10.2 $3.24 9/30/20244,220,000 shares $15.49 million +11.9%9.0%8.7 $3.67 9/15/20243,770,000 shares $14.25 million -1.1%8.1%6.1 $3.78 8/31/20243,810,000 shares $14.44 million -5.2%8.2%6.5 $3.79 8/15/20244,020,000 shares $13.79 million +0.8%8.7%6.9 $3.43 7/31/20243,990,000 shares $15.64 million +13.4%8.4%6.9 $3.92 7/15/20243,520,000 shares $11.26 million +52.4%7.4%6.1 $3.20 6/30/20242,310,000 shares $7.65 million No Change4.9%4.2 $3.31 6/15/20242,310,000 shares $8.75 million +5.5%4.9%4.5 $3.79 5/31/20242,190,000 shares $8.19 million +11.7%4.6%3.8 $3.74 5/15/20241,960,000 shares $8.25 million +6.0%4.2%2.9 $4.21 4/30/20241,850,000 shares $8.23 million -16.3%4.0%2.5 $4.45 4/15/20242,210,000 shares $10.48 million -18.2%4.8%2.4 $4.74 3/31/20242,700,000 shares $11.50 million +65.6%6.9%3.1 $4.26 3/15/20241,630,000 shares $8.35 million +21.6%5.3%2.1 $5.12 2/29/20241,340,000 shares $8.52 million +4.7%4.4%2 $6.36 2/15/20241,280,000 shares $7.16 million +63.1%4.2%2.2 $5.59 1/31/2024784,600 shares $2.99 million +28.4%2.6%2 $3.81 1/15/2024611,100 shares $1.44 million -3.6%2.0%3.2 $2.35 12/31/2023634,000 shares $1.14 million -6.0%2.1%4.4 $1.80 12/15/2023674,600 shares $1.17 million -9.6%2.2%5.3 $1.73 11/30/2023745,800 shares $1.19 million -6.9%2.5%5.8 $1.59 11/15/2023801,100 shares $1.22 million +1.1%2.7%6.4 $1.52 10/31/2023792,500 shares $1.32 million -9.7%2.6%5.9 $1.67 10/15/2023877,300 shares $1.75 million -6.9%2.9%5.8 $2.00 9/30/2023942,400 shares $1.88 million +3.6%3.1%5.3 $1.99 9/15/2023910,100 shares $1.92 million -5.1%3.0%4.2 $2.11 8/31/2023958,600 shares $2.09 million -15.2%3.0%4 $2.18 8/15/20231,130,000 shares $2.76 million -2.6%3.9%3.9 $2.44Silicon Valley Gold Rush (Ad)A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.Gates and Altman are betting big—see why 7/31/20231,160,000 shares $2.99 million -4.1%4.3%3.1 $2.58 7/15/20231,210,000 shares $3.21 million -60.2%4.5%2.7 $2.65 6/30/20233,040,000 shares $7.78 million -3.5%11.3%4.9 $2.56 6/15/20233,150,000 shares $9.51 million No Change11.7%0.8 $3.02 5/31/20233,150,000 shares $10.14 million +2.6%11.9%0.8 $3.22 5/15/20233,070,000 shares $11.45 million -14.7%11.6%0.8 $3.73 4/30/20233,600,000 shares $10.62 million -23.7%17.9%1 $2.95 4/15/20234,720,000 shares $16.38 million -2.7%23.4%1.3 $3.47 3/31/20234,850,000 shares $19.45 million +5,962.5%25.0%1.4 $4.01 3/15/202380,000 shares $160,800.00 -52.3%0.4%0.5 $2.01 2/28/2023167,700 shares $380,679.00 +49.6%0.8%1.4 $2.27 2/15/2023112,100 shares $173,755.00 -88.5%0.6%0.7 $1.55 1/31/2023973,800 shares $1.52 million +2.8%4.8%5.4 $1.56 1/15/2023947,200 shares $1.45 million +14.7%4.7%5.9 $1.53 12/30/2022826,200 shares $1.11 million +35.7%4.1%4.8 $1.34 12/15/2022609,000 shares $694,260.00 +110.1%3.0%3.7 $1.14 11/30/2022289,800 shares $420,210.00 +80.5%1.4%2 $1.45 11/15/2022160,600 shares $234,476.00 +286.1%0.8%2.1 $1.46 10/31/202241,600 shares $77,792.00 -54.8%0.2%0.7 $1.87 10/15/202292,100 shares $155,649.00 -13.3%0.5%2 $1.69 9/30/2022106,200 shares $209,214.00 -3.1%0.5%2.4 $1.97 9/15/2022109,600 shares $260,848.00 +34.6%0.5%1.1 $2.38 8/31/202281,400 shares $210,826.00 -26.7%0.4%0.8 $2.59 8/15/2022111,000 shares $309,690.00 -7.7%0.5%0.7 $2.79 7/31/2022120,300 shares $318,795.00 -6.7%0.5%0.6 $2.65 7/15/2022128,900 shares $382,833.00 -7.3%0.6%0.6 $2.97 6/30/2022139,000 shares $330,820.00 -69.0%0.6%0.5 $2.38 6/15/2022448,000 shares $1.04 million -6.6%2.0%1.8 $2.33 5/31/2022479,800 shares $1.19 million +37.9%2.2%2.3 $2.47 5/15/2022347,900 shares $702,758.00 +1.4%1.6%2.1 $2.02 4/30/2022343,200 shares $840,840.00 -18.6%1.6%3.3 $2.45 4/15/2022421,500 shares $1.54 million -21.7%2.1%4.1 $3.65 3/31/2022538,500 shares $2.18 million +12.0%2.6%6.9 $4.04 3/15/2022480,700 shares $2.19 million +0.7%2.0%6.7 $4.55 2/28/2022477,500 shares $2.90 million -2.4%2.0%3.7 $6.08 2/15/2022489,400 shares $3.85 million +6.3%2.0%3.6 $7.86 1/31/2022460,300 shares $4.39 million +27.9%1.9%3.1 $9.54 1/15/2022359,800 shares $3.71 million -34.7%1.5%2.3 $10.30 12/31/2021551,200 shares $6.05 million No Change2.3%2.7 $10.97 PYXS Short Interest - Frequently Asked Questions What is Pyxis Oncology's current short interest? Short interest is the volume of Pyxis Oncology shares that have been sold short but have not yet been covered or closed out. As of March 31st, traders have sold 7,340,000 shares of PYXS short. 16.77% of Pyxis Oncology's shares are currently sold short. Learn More on Pyxis Oncology's current short interest. What is a good short interest ratio for Pyxis Oncology? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PYXS shares currently have a short interest ratio of 12.0. Learn More on Pyxis Oncology's short interest ratio. Which institutional investors are shorting Pyxis Oncology? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Pyxis Oncology: Group One Trading LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Pyxis Oncology? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 16.77% of Pyxis Oncology's floating shares are currently sold short. Is Pyxis Oncology's short interest increasing or decreasing? Pyxis Oncology saw a increase in short interest in March. As of March 31st, there was short interest totaling 7,340,000 shares, an increase of 6.1% from the previous total of 6,920,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Pyxis Oncology's float size? Pyxis Oncology currently has issued a total of 61,590,000 shares. Some of Pyxis Oncology's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Pyxis Oncology currently has a public float of 43,770,000 shares. How does Pyxis Oncology's short interest compare to its competitors? 16.77% of Pyxis Oncology's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Pyxis Oncology: Y-mAbs Therapeutics, Inc. (10.62%), Acelyrin, Inc. (4.99%), Immutep Limited (3.21%), ProKidney Corp. (12.82%), Humacyte, Inc. (21.57%), iTeos Therapeutics, Inc. (5.54%), Solid Biosciences Inc. (12.85%), Corvus Pharmaceuticals, Inc. (11.15%), CARGO Therapeutics, Inc. (18.87%), Cidara Therapeutics, Inc. (6.90%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short Pyxis Oncology stock? Short selling PYXS is an investing strategy that aims to generate trading profit from Pyxis Oncology as its price is falling. PYXS shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Pyxis Oncology? A short squeeze for Pyxis Oncology occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PYXS, which in turn drives the price of the stock up even further. How often is Pyxis Oncology's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PYXS, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies YMAB Short Interest Data SLRN Short Interest Data IMMP Short Interest Data PROK Short Interest Data HUMA Short Interest Data ITOS Short Interest Data SLDB Short Interest Data CRVS Short Interest Data CRGX Short Interest Data CDTX Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PYXS) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PYXS Stock Free PYXS Stock Alerts